Whether JAK1/2 inhibitors should be continually administered close to the start of conditioning therapy is being investigated in the ongoing trials by the Myeloproliferative Disorders Research Consortium (NCT01790295) and the Fred Hutchinson Cancer Research Center (NCT02251821). The gene discussed is JAK1; the disease is myeloproliferative disorder.